Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price

References

• (AIHW), A.I.o.H.a.W. Cancer in Australia 2019. 2019; Available from: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2019/summary.
   Google Scholar
• Surveillance, E., and End Results Program (SEER). SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer. 2020. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html.
   Google Scholar
• Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013; 23(1) :38–45.
   PubMed Web of Science ®Google Scholar
• Australia AGS. Pharmaceutical Benefits Schedule Item Reports. 2021. Available from: http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp.
   Google Scholar
• (PBAC), A.P.B.A.C. Public Summary Document: Everolimus (RCC) March 2014. 2014; Available from: https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2014-03/everolimus-rcc.
   Google Scholar
• (PBS), A.P.B.S. Schedule of Pharmaceutical Benefits Summary of Changes Effective 1 June 2018. 2018; Available from: https://www.pbs.gov.au/publication/schedule/2018/06/2018-06-01-general-soc.pdf.
   Google Scholar
• Kim H, ISPOR Australia Chapter executive committee, J, Byrnes S. Goodall. Health technology assessment in australia: the pharmaceutical benefits advisory committee and medical services advisory committee. Value Health Reg Issues. 2021; 24 :6–11.
   PubMedGoogle Scholar
• Australian Government, D.o.H. Deeds Agreement - Background. 2019. Available from: http://www.pbs.gov.au/info/industry/listing/elements/deeds-agreement/b-background.
   Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373(19) :1803–1813.
   PubMed Web of Science ®Google Scholar
• (PBAC), A.P.B.A.C. Public Summary Document: Nivolumab (RCC) July 2016. 2016; Available from: http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2016-07/nivolumab-psd-july-2016.
   Google Scholar
• (PBAC), A.P.B.A.C. Public Summary Document: Nivolumab (RCC) March 2017. 2017; Available from: http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2017-03/nivolumab-rcc-psd-march-2017.
   Google Scholar
• Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020; 126(18) :4156–4167.
   PubMed Web of Science ®Google Scholar
• Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health. 2010; 13(1) :55–60.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, del Muro JG, Grande E, et al. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J Clin Pharm Ther. 2010; 35(4) :429–438.
   PubMed Web of Science ®Google Scholar
• Mihajlovic J, et al. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia. Clin Ther. 2013; 35(12) :1909–1922.
   PubMed Web of Science ®Google Scholar
• Chandiwana D, Perrin A, Sherman S. A cost effectivness analysis of everolimus compared with axitinib in the treatment of metastatic renal cell carcinoma in the United Kingdom. Value Health. 2014; 17(7) :A640.
   PubMed Web of Science ®Google Scholar
• (PBAC), A.P.B.A.C. Public Summary Document: Nivolumab (RCC) November 2016. 2016; Available from: http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2016-11/nivolumab-rcc-psd-november-2016.
   Google Scholar
• Hoyle MW, Henley W. improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011; 11(1) :139.
   PubMed Web of Science ®Google Scholar
• Latimer N. NICE Decision Support Unit. NICE DSU TECHNICAL SUPPORT DOCUMENT 14: SURVIVAL ANALYSIS FOR ECONOMIC EVALUATIONS ALONGSIDE CLINICAL TRIALS - EXTRAPOLATION WITH PATIENT-LEVEL DATA. 2013. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf.
   Google Scholar
• Australian Government, D.o.H. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) Version 5.0. 2016. Available from: https://pbac.pbs.gov.au/.
   Google Scholar
• Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7) :994–1003.
   PubMed Web of Science ®Google Scholar
• Mahon S, Bullement A, Willis A, et al. Cost effectiveness of nivolumab for patients with advanced, previously treated renal cell carcinoma in Scotland. Value Health. 2017; 20(9):A440.
   Web of Science ®Google Scholar
• Viney R, Norman R, King MT, et al. Time trade-off derived EQ-5D weights for Australia. Value Health. 2011; 14(6) :928–936.
   PubMed Web of Science ®Google Scholar
• (PBS), A.P.B.S. Schedule of Pharmaceutical Benefits Effective 1 July 2016. 2016; Available from: https://www.pbs.gov.au/info/publication/schedule/archive#_2016.
   Google Scholar
• (PBAC), A.P.B.A.C. Public Summary Document: Everolimus (RCC) July 2010. 2010; Available from: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2010-07/pbac-psd-Everolimus-july10.
   Google Scholar
• (PBS), A.P.B.S. Schedule of Pharmaceutical Benefits Effective 1 June 2018. 2018; Available from: https://www.pbs.gov.au/publication/schedule/2018/06/2018-06-01-general-schedule.pdf.
   Google Scholar
• (IHPA), A.I.H.P.A. National Hospital Cost Data Collection, AR-DRG Cost Weight tables V8.0x, Round 21 (Financial year 2016-17). 2019. Available from: https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-ar-drg-cost-weight-tables-v80x-round-21.
   Google Scholar
• Briggs A, Claxton K, and M. Sculpher Decision modelling for health economic evaluation. Oxford Handbook in Health Economic Evaluation. 2007. Great Britain: Oxford University Press.
   Google Scholar
• Rohatgi A. WebPlotDigitizer. 2020. Available from: https://automeris.io/WebPlotDigitizer/.
   Google Scholar
• El Osta B, Hu F, Sadek R, et al. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017; 119:1–12.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12 :9.
   PubMed Web of Science ®Google Scholar
• (PBAC), A.P.B.A.C. Nivolumab (Adj Melanoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®. 2019. Available from: http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2019-03/nivolumab-melanoma-psd-march-2019.
   Google Scholar
• (FDA), U.F.a.D.A. Prescribing information for AFINITOR (everolimus). 2009. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf.
   Google Scholar
• Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47(9):1287–1298.
   PubMed Web of Science ®Google Scholar